Key points are not available for this paper at this time.
This review summarizes how sophisticated imaging, immunohistochemical testing, and molecular-profiling tools are changing the approach to cancer of unknown primary site. Increasingly, treatment decisions are personalized on the basis of the mutational status of a patient's tumor.
Varadhachary et al. (Wed,) studied this question.